Fingolimod 0.5 mg

DRUG5 trials

Conditions

Coronavirus Disease (COVID-19)Multiple SclerosisRelapsing Remitting Multiple SclerosisRelapsing-remitting Multiple Sclerosis

Phase 2

Fingolimod in COVID-19

WithdrawnNCT04280588

First Affiliated Hospital of Fujian Medical UniversityCoronavirus Disease (COVID-19)

Start: 2020-02-22End: 2020-07-01Updated: 2020-11-13

Phase 3

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

CompletedNCT00289978

NovartisRelapsing-remitting Multiple Sclerosis

Start: 2006-01-31End: 2009-07-31Updated: 2012-04-11

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

CompletedNCT00340834

NovartisMultiple Sclerosis

Start: 2006-05-31End: 2011-07-31Updated: 2017-09-21

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

CompletedNCT00662649

NovartisMultiple Sclerosis

Start: 2008-02-29End: 2011-06-30Updated: 2012-07-12

Phase 4

Fingolimod Effect on Cytokine and Chemokine Levels

CompletedNCT02373098

Novartis PharmaceuticalsRelapsing Remitting Multiple Sclerosis

Start: 2015-03-31End: 2017-01-18Updated: 2019-09-30

Multiple Sclerosis Journal2025-04-18

Group sequential methods for the Mann-Whitney parameter

Statistical Methods in Medical Research2022-06-139 citations

The COVID-19 pandemic and the use of MS disease-modifying therapies

Multiple Sclerosis and Related Disorders2020-03-27190 citations

Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.

2016-11-1029 citations

Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.

2016-11-0326 citations

Teriflunomide Exhibits Similar Results to Fingolimod in Number Needed to Treat Analysis (P6.171)

Neurology2016-04-05

Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.

2015-08-2023 citations

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

Journal of Neurology Neurosurgery & Psychiatry2015-06-25163 citations

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).

2013-12-1210 citations

Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study

Multiple Sclerosis and Related Disorders2013-11-0513 citations

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

2012-10-0185 citations

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

2012-04-10120 citations

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

2011-05-13153 citations

Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS).

2010-10-1117 citations

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

2010-01-201857 citations

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

2010-01-201547 citations

Fingolimod 0.5 mg

Sponsors

Conditions

Phase 2

Phase 3

Phase 4

Related Papers